Waystar (WAY) investor relations material

Market positioning and platform strategy

• Focuses on helping healthcare providers maximize reimbursement and reduce costs through an end-to-end, cybersecure platform, differentiating from legacy and fragmented solutions.

• Emphasizes high ROI and lower total cost of ownership, with a strong client reference network supporting new business.

• Achieves a 99% first pass clean claim rate, significantly reducing administrative burden compared to industry averages.

• Replaces both outdated manual processes and underperforming vendors, consolidating multiple solutions into a single platform.

• Growing demand for single-vendor solutions, especially among health systems and large ambulatory enterprises.

Acquisitions and technology integration

• The $1.25B Iodine acquisition expands capabilities into clinical documentation, supporting the vision of the “perfect undeniable claim.”

• Iodine’s AI modules convert unstructured clinical notes into structured claim codes, improving claim accuracy and efficiency.

• Integration of Iodine is expected to accelerate enhancements in prior authorization and other platform solutions.

• Over 160 AI modules from Iodine are being leveraged to expand and accelerate product development.

AI innovation and product development

• Generative AI products, including the Altitude suite, have seen strong early adoption and deliver measurable ROI.

• AI-driven solutions reduce prior authorization time by 70% and denials/appeals processing time by 90%.

• Monetization includes annual price uplifts and new SKUs for AI products, with a long-term layering effect on revenue.

• AI solutions are increasingly comprising a larger share of the sales pipeline and bookings.

• Ongoing innovation showcases and future plans include agentic AI and expansion of use cases.